65,437 trials
Non-Hodgkin's Lymphoma · Lymphoma, B-cell · Lymphoma, Low-grade
Primary: Objective Clinical Response: Complete Response (CR) or Partial Response (PR) at Week 24, or, in the Event of Lengthened Cycle Intervals, at the End of Cycle 8. — 1; 1…
Chronic Hepatitis B
Primary: Number of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/mL (<69 IU/mL) — 74 Participants
Asthma
Primary: Rate of Clinically Significant Asthma Exacerbations Per Patient in the 24-week Fixed-dose Steroid Treatment Period — 0.45; 0.64 Exacerbations per patient per 24-weeks
Helicobacter Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 92; 95 participants
Attention-Deficit/Hyperactivity Disorder
Primary: Percent of Treatment Failures at up to 6 Weeks — 8.9; 75.0 Percent of participants — p=<0.0001
Non-Small Cell Lung Cancer
Primary: Number of Participants With Dose-limiting Toxicities (DLT) Due to Vorinostat Administered in Combination With Standard Dose of Gemcitabine Plus Either Cisplatin or…
Major Depressive Disorder
Primary: Midazolam Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Midazolam Alone and When Coadministered With DVS…
Carcinoma, Non-Small Cell Lung
Primary: Overall Survival (OS) — 9.0; 8.5 Months — p=0.1933
Dysfunctional Hemodialysis Catheters
Primary: Percentage of Participants Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1 — 34.1 Percentage of participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c at Week 12 — 0.63; -0.24; -0.25 Percent — p=<0.0001
Sepsis
Primary: Amount of Study Drug Required to Achieve Initial Hemodynamic Stabilization — 1379; 1709 Milliliter — p=0.0185
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: The Number of Subjects With Adverse Events — 10 participants
Asthma
Primary: Change (%) From Baseline in FcεRI (High-affinity IgE Receptor) Expression on Blood Basophils and Dendritic Cells After 16 Weeks of Treatment With Omalizumab as Compared…
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (Glycosylated Hemoglobin) at Week 18 — -0.07; -0.54 percent — p=< 0.0001
Schizophrenia
Primary: Number of Participants With All-cause Mortality — 64; 61; 40; 44 participants — p=0.05